Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City (ACCP)

Access Pharmaceuticals, Inc. (OTCBB: ACCP) is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation platinum chemotherapeutic drug and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas. 

The Company has announced that it will be presenting at a joint international symposium of the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) on Supportive Care in Cancer, in which the results of a recent interim analysis of data from an ongoing MuGard clinical trial will be shared.

On Thursday June 28th, a podium presentation will be made by one of the lead investigators in the study, and on Friday June 29th results will be presented in a poster on display. In addition to these presentations, "Access will have its MuGard booth in the commercial exhibit hall to educate the attendees on the clinical benefit MuGard offers patients undergoing cancer treatment. The annual MASCC/ISOO Symposium is the preeminent international conference to focus on supportive care in oncology and will be held this week at the Hilton New York Hotel on Thursday, June 28th – Saturday, June 30th."

Read more at PRNewswire.com.